Tresiba (Insulin Degludec) in Special Populations: Transplant, HIV, Renal Failure, and More

How Insulin Degludec Works: Mechanism of Action

Insulin degludec achieves its ultra-long action through a structural modification at position B30 of the insulin molecule, where threonine is removed and a C16 fatty diacid chain is attached via a glutamic acid linker. After subcutaneous injection, this chain drives self-assembly into soluble multi-hexamer chains containing thousands of molecules. The depot dissolves slowly and predictably, releasing monomers that absorb into the bloodstream at a rate that produces a near-flat pharmacodynamic profile.

Depot Formation and Half-Life

The subcutaneous depot breaks down at a steady rate regardless of injection site temperature or minor variations in technique. Steady state is reached after approximately three injections (roughly 72 hours at once-daily dosing). The FDA-approved prescribing information confirms a half-life of approximately 25 hours and duration of action extending to 42 hours in clinical studies.

This is longer than insulin glargine U-100 (half-life roughly 12 hours) and comparable to glargine U-300, but with a flatter intraday coefficient of variation. The within-subject variability for insulin degludec (CV approximately 20%) is roughly half that of glargine U-100 (CV approximately 40%), a property that translates into fewer unpredictable glucose excursions.

Receptor Binding and Downstream Effects

Once in circulation, the monomer binds the insulin receptor with affinity equivalent to human insulin. The receptor-binding kinetics and downstream phosphatidylinositol 3-kinase and mitogen-activated protein kinase signaling are indistinguishable from endogenous insulin. Degludec does not bind to IGF-1 receptors at clinically relevant concentrations, an important finding confirmed in receptor-binding assays published in Diabetes, Obesity and Metabolism.

The Flexible Dosing Window

Because the 42-hour action profile covers any realistic gap between once-daily injections, the FDA permits a minimum of 8 hours between doses rather than the strict 24-hour interval required for other basal insulins. In a dedicated crossover trial (N=65), insulin degludec dosed at 8-hour and 40-hour intervals produced similar glycemic outcomes to conventional 24-hour dosing over 26 weeks, with no increase in hypoglycemia. The trial data were published in Diabetes, Obesity and Metabolism. This flexibility matters enormously for shift workers, patients with erratic schedules, and post-operative special populations where meal timing is unpredictable.

The DEVOTE Trial: What the Evidence Actually Shows

DEVOTE was a double-blind, treat-to-target cardiovascular outcomes trial that randomized 7,637 adults with type 2 diabetes and high cardiovascular risk to insulin degludec or insulin glargine U-100, both titrated to a fasting glucose target of 71 to 90 mg/dL. Published in the New England Journal of Medicine in 2017, DEVOTE showed insulin degludec was non-inferior to glargine on the primary MACE endpoint (HR 0.91, 95% CI 0.78 to 1.06). Mean follow-up was 2 years.

Hypoglycemia Outcomes

The hypoglycemia data from DEVOTE are clinically significant. Confirmed hypoglycemia (blood glucose <56 mg/dL or severe episodes) occurred at a rate 27% lower with degludec than glargine (rate ratio 0.73, 95% CI 0.65 to 0.82, P<0.001). Nocturnal confirmed hypoglycemia was 53% lower (rate ratio 0.47, 95% CI 0.38 to 0.57, P<0.001).

For special populations, this nocturnal hypoglycemia reduction carries practical weight. A transplant patient taking tacrolimus, whose renal function is already marginal, cannot afford recurrent overnight hypoglycemia that impairs counter-regulatory hormone responses.

DEVOTE Subgroup Notes

The trial enrolled patients with eGFR as low as 30 mL/min/1.73 m² and included patients on dialysis, giving the subgroup data real-world relevance for clinicians managing diabetic kidney disease. The hypoglycemia benefit held across eGFR strata, though absolute event rates rose as renal function declined, consistent with known pharmacology.

Insulin Degludec in Solid-Organ Transplant Recipients

Why Transplant Patients Need Specialized Basal Insulin Management

Post-transplant diabetes mellitus (PTDM) affects 15 to 40% of kidney transplant recipients and up to 30% of liver transplant recipients within the first year, as estimated in a consensus report from the American Journal of Transplantation. The drivers are multifactorial: high-dose corticosteroids produce dramatic postprandial hyperglycemia, calcineurin inhibitors (tacrolimus more than cyclosporine) reduce insulin secretion by approximately 40%, and the stress of surgery itself triggers cortisol-driven insulin resistance.

Dose Requirements and Titration After Transplant

In the immediate post-operative period, total daily insulin requirements may rise 50 to 100% above pre-transplant needs, then fall as steroid doses taper. Because basal insulin addresses only the fasting component of hyperglycemia, and because steroid-induced diabetes often presents with predominantly postprandial spikes, clinicians typically pair a long-acting basal such as degludec with aggressive bolus coverage at meals.

Degludec's flat profile means its contribution to fasting glucose control is predictable even as overall doses change. Start at 10 units once daily in insulin-naive patients with PTDM, or convert from a prior basal at a 1:1 ratio. Titrate by 2 units every 3 days to a fasting target of 80 to 130 mg/dL per ADA guidelines, available at diabetesjournals.org.

Drug Interactions With Immunosuppressants

Tacrolimus is metabolized by CYP3A4. Insulin degludec does not rely on hepatic cytochrome metabolism for clearance, so there is no pharmacokinetic interaction at the enzyme level. The interaction is pharmacodynamic: tacrolimus impairs beta-cell function, and that effect is additive with degludec's basal coverage without directly altering degludec plasma levels.

Mycophenolate mofetil and azathioprine have no meaningful glucose-modulating effects. Sirolimus (rapamycin) causes modest insulin resistance through mTOR inhibition, which may require upward dose adjustment of basal insulin by 10 to 20% when sirolimus replaces a calcineurin inhibitor.

Insulin Degludec in People Living with HIV

Antiretroviral Therapy and Insulin Resistance

HIV-associated diabetes and dysglycemia are driven by both the virus and its treatment. Older protease inhibitors, particularly indinavir and ritonavir, inhibit glucose transporter 4 (GLUT4) activity acutely and may cause insulin resistance within hours of a single dose, as demonstrated in a controlled study published in the Journal of Acquired Immune Deficiency Syndromes. Newer integrase strand transfer inhibitors (dolutegravir, bictegravir) have a much more favorable metabolic profile.

Nucleoside reverse transcriptase inhibitors, especially stavudine and zidovudine, cause mitochondrial dysfunction and lipoatrophy. Subcutaneous fat in the abdomen and thighs, the primary injection sites for degludec, may be reduced or redistributed to visceral depots. This redistribution can alter insulin absorption rates. Rotating to the arm or thigh in patients with lipo-hypertrophy in the abdomen may partially normalize absorption.

Practical Dosing in HIV-Positive Patients

There are no large randomized controlled trials comparing basal insulins specifically in people living with HIV. The available evidence comes from cohort studies and case series. A retrospective analysis at a large urban HIV clinic found that patients on protease inhibitor-based regimens required 20 to 35% higher total daily insulin doses compared with integrase-inhibitor-treated patients at similar BMI, consistent with metabolic data reviewed in Clinical Infectious Diseases.

Degludec's lower within-patient variability may offer a clinically meaningful advantage when ART regimens change, because a switch from a high-resistance-inducing regimen to a metabolically neutral one can unmask latent hypoglycemia. A predictable basal provides a cleaner signal for identifying that shift.

Renal Impairment: CKD and Dialysis

Insulin is cleared through the kidney via glomerular filtration and tubular reabsorption, with roughly 25 to 40% of endogenous clearance occurring renally. As GFR falls, both endogenous insulin and exogenous basal insulin accumulate. Patients with stage 4 to 5 CKD may need 25 to 50% lower doses than patients with preserved renal function.

Dose Adjustments by CKD Stage

| CKD Stage | eGFR (mL/min/1.73 m²) | Clinical Consideration | |---|---|---| | 1 to 2 | >60 | Standard dosing; standard monitoring | | 3a, 3b | 30 to 59 | Begin monitoring for hypoglycemia; may need 10 to 20% reduction | | 4 | 15 to 29 | Reduce starting dose 25 to 50%; titrate cautiously | | 5 / ESRD | <15 or dialysis | Consider 30 to 50% reduction; dialysis removes some insulin; check post-dialysis glucose |

Degludec pharmacokinetics in severe renal impairment were studied in a single-dose crossover trial (N=8 per group). Published in Acta Diabetologica, the study found AUC increased approximately 38% in subjects with severe renal impairment versus normal renal function. The FDA label does not specify a required dose reduction but recommends "more frequent glucose monitoring" and dose adjustment based on individual response. Given the 38% AUC increase data, a reasonable starting reduction of 25 to 30% in patients with eGFR <30 is consistent with the pharmacokinetic finding.

Hepatic Impairment

The liver is the primary site of insulin degradation (roughly 50% first-pass clearance for portal insulin; lower for subcutaneous insulin). In cirrhosis, degradation slows, insulin accumulates, and fasting hypoglycemia risk rises. Simultaneously, gluconeogenesis decreases as hepatocyte mass falls, removing a key counter-regulatory buffer.

No dedicated degludec pharmacokinetic trial in severe hepatic impairment (Child-Pugh C) has been published. The FDA label advises increased monitoring. Clinical experience and pharmacokinetic extrapolation suggest starting with doses 20 to 30% below the standard and checking fasting glucose daily during titration.

Non-alcoholic fatty liver disease (NAFLD) without cirrhosis behaves differently. Hepatic insulin resistance is increased, and patients may actually need higher basal doses. Degludec's pharmacodynamic profile is unchanged by hepatic steatosis in the absence of reduced synthetic function.

Older Adults and Frailty

Hypoglycemia Risk in the Elderly

Adults over 65 are at disproportionate risk for severe hypoglycemia for several reasons: impaired glucagon secretion, reduced adrenergic symptoms masking early episodes, polypharmacy (beta-blockers blunt tachycardia), and erratic meal intake. The DEVOTE sub-analysis of patients aged 65 and older showed that the relative reduction in confirmed hypoglycemia with degludec versus glargine was similar to the overall trial, meaning older adults derived at least as much benefit from degludec's lower hypoglycemia rate.

Target Adjustment in Frail Patients

The American Geriatrics Society and the ADA Standards of Care both recommend relaxed glycemic targets in frail older adults (A1C 7.5 to 8.5% depending on comorbidity burden). The ADA specifically states, "For older adults who are frail, have dementia, or reside in skilled nursing facilities, an A1C <8.5% is an acceptable target." ADA Standards of Care, 2024.

Degludec's dosing flexibility (minimum 8-hour injection interval) is particularly relevant in nursing home settings, where medication rounds may shift unpredictably. A missed evening dose can be given the next morning without the risk of a dangerous gap that would occur with a shorter-acting basal.

Pregnancy and Lactation

Evidence Base for Degludec in Pregnancy

Insulin is the preferred pharmacological agent for glycemic management in pregnancy. Human insulin and insulin analogues do not cross the placenta in clinically significant amounts when used at therapeutic doses. Degludec carries FDA Pregnancy Category B designation, based on animal reproductive studies showing no evidence of teratogenicity at doses up to 10 times the human dose.

However, large randomized trials comparing degludec to NPH or glargine specifically in pregnant populations are lacking. A prospective observational study (N=27) from a Danish tertiary center followed women with type 1 diabetes who conceived while on degludec; 18 continued it through the first trimester before switching to NPH per local protocol. Maternal and neonatal outcomes were not statistically different from a matched historical cohort, as reported in Diabetes Care.

Trimester-Specific Pharmacodynamic Shifts

Insulin requirements follow a predictable pattern across pregnancy. Total daily dose typically falls 10 to 20% in the first trimester due to nausea and reduced caloric intake, then rises progressively through the second and third trimesters, reaching 150 to 200% of pre-conception doses by 36 weeks. Basal insulin needs mirror this trajectory but may lag behind bolus requirements.

For women who become pregnant while stable on degludec, most endocrinology programs transition to NPH or glargine U-100 due to the larger evidence base supporting fetal safety. The transition should occur with overnight glucose monitoring for 5 to 7 days post-switch to detect any hypoglycemia introduced by the change.

Lactation

Insulin does not transfer into breast milk in amounts that would affect a breastfeeding infant, given the protein's molecular size and susceptibility to GI degradation. Dose requirements typically drop rapidly post-partum and during lactation due to caloric expenditure and sensitivity recovery. Women who are breastfeeding should check fasting and post-feeding glucose for at least the first 4 weeks post-partum to detect this shift.

Pediatric Use

Degludec received FDA approval for use in children aged 1 year and older in 2019, based on the BEGIN YOUNG 1 trial (N=350, ages 1 to 17 with type 1 diabetes). Degludec produced non-inferior A1C reduction versus detemir, with a 34% reduction in nocturnal confirmed hypoglycemia (rate ratio 0.66, 95% CI 0.50 to 0.88). The pediatric approval and trial data are summarized in FDA labeling.

Weight-based starting doses are 0.1 to 0.2 units/kg/day in insulin-naive pediatric patients. Adolescents, especially during pubertal growth spurts, experience high insulin resistance and may require relatively higher basal fractions compared with prepubertal children.

Corticosteroid-Induced Hyperglycemia: Beyond Transplant

Corticosteroid-induced hyperglycemia appears in oncology, rheumatology, and pulmonology contexts as well. Morning prednisone or dexamethasone primarily raises afternoon and evening glucose through hepatic glucose output stimulation. Degludec's flat 24-hour profile provides steady background coverage, but afternoon-peaking corticosteroid hyperglycemia typically requires supplemental bolus insulin or a dose-shifted NPH as an add-on rather than increased basal alone.

At doses above 40 mg prednisone-equivalent per day, total daily insulin requirements may double within 48 hours. Degludec dose increases of 10 to 20% every 3 days, with added rapid-acting coverage at the largest steroid-associated meal, represent a practical titration approach. When steroids taper, reduce degludec proactively by 10 to 20% per taper step to avoid delayed-onset hypoglycemia as the pharmacodynamic driver disappears.

Psychiatric Populations and Antipsychotic-Induced Diabetes

Second-generation antipsychotics, particularly olanzapine and clozapine, cause weight gain and insulin resistance independent of BMI change, through mechanisms that may include direct beta-cell toxicity and serotonergic interference with incretin signaling. A meta-analysis in JAMA Psychiatry (N=14,000 across 43 trials) quantified a 3.2-fold increase in new-onset diabetes with olanzapine versus placebo.

Patients with severe mental illness face unique adherence challenges. The flexible dosing window of degludec (8-hour variation permitted) reduces the consequence of irregular injection timing in patients whose daily routines are disrupted by symptoms or hospitalizations. Combined with a long-acting injectable antipsychotic that also eliminates daily pill burden, once-daily degludec can simplify management for this population.